International Journal of Endocrinology and Metabolism

Published by: Kowsar

Female Pattern Hair Loss

Ingrid Herskovitz 1 and Antonella Tosti 1 , *
Authors Information
1 Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, USA
Article information
  • International Journal of Endocrinology and Metabolism: October 01, 2013, 11 (4); e9860
  • Published Online: October 1, 2013
  • Article Type: Review Article
  • Received: December 20, 2012
  • Revised: April 24, 2013
  • Accepted: May 5, 2013
  • DOI: 10.5812/ijem.9860

To Cite: Herskovitz I, Tosti A. Female Pattern Hair Loss, Int J Endocrinol Metab. 2013 ; 11(4):e9860. doi: 10.5812/ijem.9860.

Copyright © 2013, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Female Pattern Hair Loss
2. Epidemiology
3. Etiopathogenesis
4. Clinical Features
5. Diagnosis
6. Laboratory Tests
7. Differential Diagnosis
8. Treatment of FPHL
9. General Care
10. Conclusions
  • 1. Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011; 164(1): 5-15[DOI][PubMed]
  • 2. Leavitt M. Understanding and management of female pattern alopecia. Facial Plast Surg. 2008; 24(4): 414-27[DOI][PubMed]
  • 3. Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol. 2004; 123(3): 455-7[DOI][PubMed]
  • 4. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001; 144(2): 297-304[PubMed]
  • 5. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001; 27(1): 53-4[PubMed]
  • 6. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988; 19(5 Pt 1): 831-6[PubMed]
  • 7. Montalto J, Whorwood CB, Funder JW, Yong AB, Callan A, Davies HE, et al. Plasma C19 steroid sulphate levels and indices of androgen bioavailability in female pattern androgenic alopecia. Clin Endocrinol (Oxf). 1990; 32(1): 1-12[PubMed]
  • 8. Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001; 45(3 Suppl)-80[PubMed]
  • 9. The androgen resistance syndromes: 5a-reductase deficiency, testicular feminization, and related disorders. 1983;
  • 10. Glaser RL, Dimitrakakis C, Messenger AG. Improvement in scalp hair growth in androgen-deficient women treated with testosterone: a questionnaire study. Br J Dermatol. 2012; 166(2): 274-8[DOI][PubMed]
  • 11. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009; 88(1): 32-45[DOI][PubMed]
  • 12. Inui S, Itami S. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. J Dermatol Sci. 2011; 61(1): 1-6[DOI][PubMed]
  • 13. Winiarska A, Mandt N, Kamp H, Hossini A, Seltmann H, Zouboulis CC, et al. Effect of 5alpha-dihydrotestosterone and testosterone on apoptosis in human dermal papilla cells. Skin Pharmacol Physiol. 2006; 19(6): 311-21[DOI][PubMed]
  • 14. Redler S, Brockschmidt FF, Tazi-Ahnini R, Drichel D, Birch MP, Dobson K, et al. Investigation of the male pattern baldness major genetic susceptibility loci AR/EDA2R and 20p11 in female pattern hair loss. Br J Dermatol. 2012; 166(6): 1314-8[DOI][PubMed]
  • 15. Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009; 161(2): 289-94[DOI][PubMed]
  • 16. Redler S, Birch MP, Drichel D, Dobson K, Brockschmidt FF, Tazi-Ahnini R, et al. Investigation of variants of the aromatase gene (CYP19A1) in female pattern hair loss. Br J Dermatol. 2011; 165(3): 703-5[DOI][PubMed]
  • 17. Redler S, Tazi-Ahnini R, Drichel D, Birch MP, Brockschmidt FF, Dobson K, et al. Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified. Exp Dermatol. 2012; 21(5): 390-3[DOI][PubMed]
  • 18. Mahmoudi H, Redler S, Birch P, Drichel D, Dobson K, Tazi-Ahnini R, et al. Selected variants of the melanocortin 4 receptor gene (MC4R) do not confer susceptibility to female pattern hair loss. Arch Dermatol Res. 2013; 305(3): 249-53[DOI][PubMed]
  • 19. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977; 97(3): 247-54[PubMed]
  • 20. Olsen EA. Androgenetic alopecia. In: Disorders of hair growth: diagnosis and treatment. 1994; : 257-283
  • 21. Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol. 1988; 18(5 Pt 1): 1073-7[PubMed]
  • 22. Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol. 2012; 67(5): 1040-8[DOI][PubMed]
  • 23. Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol. 2006; 55(5): 799-806[DOI][PubMed]
  • 24. de Lacharriere O, Deloche C, Misciali C, Piraccini BM, Vincenzi C, Bastien P, et al. Hair diameter diversity: a clinical sign reflecting the follicle miniaturization. Arch Dermatol. 2001; 137(5): 641-6[PubMed]
  • 25. Arias-Santiago S, Gutierrez-Salmeron MT, Castellote-Caballero L, Buendia-Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol. 2010; 63(3): 420-9[DOI][PubMed]
  • 26. Yi SM, Son SW, Lee KG, Kim SH, Lee SK, Cho ER, et al. Gender-specific association of androgenetic alopecia with metabolic syndrome in a middle-aged Korean population. Br J Dermatol. 2012; 167(2): 306-13[DOI][PubMed]
  • 27. Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol. 1996; 35(6): 899-906[PubMed]
  • 28. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002; 27(5): 389-5[PubMed]
  • 29. Gilmore S, Sinclair R. Chronic telogen effluvium is due to a reduction in the variance of anagen duration. Australas J Dermatol. 2010; 51(3): 163-7[DOI][PubMed]
  • 30. Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol. 2012; 23(11): 2879-84[DOI][PubMed]
  • 31. Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A. Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol. 2011; 64(3): 604-6[DOI][PubMed]
  • 32. Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P, Tosti A. Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol. 2011; 33(4): 345-50[DOI][PubMed]
  • 33. Miteva M, Misciali C, Fanti PA, Tosti A. Histopathologic features of alopecia areata incognito: a review of 46 cases. J Cutan Pathol. 2012; 39(6): 596-602[DOI][PubMed]
  • 34. Rebora A. Alopecia areata incognita: a comment. Clinics (Sao Paulo). 2011; 66(8): 1481-2[PubMed]
  • 35. Tosti A, Whiting D, Iorizzo M, Pazzaglia M, Misciali C, Vincenzi C, et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol. 2008; 59(1): 64-7[DOI][PubMed]
  • 36. Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol. 1994; 130(6): 770-4[PubMed]
  • 37. Chew AL, Bashir SJ, Wain EM, Fenton DA, Stefanato CM. Expanding the spectrum of frontal fibrosing alopecia: a unifying concept. J Am Acad Dermatol. 2010; 63(4): 653-60[DOI][PubMed]
  • 38. MacDonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a review of 60 cases. J Am Acad Dermatol. 2012; 67(5): 955-61[DOI][PubMed]
  • 39. Tosti A, Piraccini BM, Iorizzo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol. 2005; 52(1): 55-60[DOI][PubMed]
  • 40. Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011; 9 Suppl 6-57[DOI][PubMed]
  • 41. Whiting DA, Jacobson C. Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol. 1992; 31(11): 800-4[PubMed]
  • 42. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011; 65(6): 1126-1134 e2[DOI][PubMed]
  • 43. Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol. 1989; 69(5): 395-8[PubMed]
  • 44. Vexiau P, Chaspoux C, Boudou P, Fiet J, Jouanique C, Hardy N, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002; 146(6): 992-9[PubMed]
  • 45. Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol. 1996; 35(11): 770-8[PubMed]
  • 46. Christy NA, Franks AS, Cross LB. Spironolactone for hirsutism in polycystic ovary syndrome. Ann Pharmacother. 2005; 39(9): 1517-21[DOI][PubMed]
  • 47. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year followup study. J Cutan Med Surg. 2002; 6(6): 541-5[DOI][PubMed]
  • 48. Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007; 357(16): 1620-30[DOI][PubMed]
  • 49. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005; 152(3): 466-73[DOI][PubMed]
  • 50. Rushton D HUGH, Futterweit WALTER, Kingsley DAVID H, Kingsley Philip, Norris Michael J. Quantitative assessment of spironolactone treatment in women with diffuse androgen-dependent alopecia. J Soc Cosmet Chem. 1991; 42: 317-325
  • 51. Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011; 45(4): 469-75[DOI][PubMed]
  • 52. Bruni V, Peruzzi E, Dei M, Nannini S, Seravalli V, Sisti G, et al. Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril. 2012; 98(4): 1047-52[DOI][PubMed]
  • 53. Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000; 43(5 Pt 1): 768-76[DOI][PubMed]
  • 54. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006; 142(3): 298-302[DOI][PubMed]
  • 55. Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007; 23(3): 142-5[DOI][PubMed]
  • 56. Trueb RM. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004; 209(3): 202-7[DOI][PubMed]
  • 57. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005; 4(5): 637-40[PubMed]
  • 58. Camacho F, Tosti A. [Medical treatment of female alopecia]. Monogr Dermatol. 2005; 18(6): 92
  • 59. Hair loss in women. Semin Cutan Med Surg. : 19-32
  • 60. Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, Ibrahim M. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013; 27(6): 686-93[DOI][PubMed]
  • 61. Kondo S, Hozumi Y, Aso K. Organ culture of human scalp hair follicles: effect of testosterone and oestrogen on hair growth. Arch Dermatol Res. 1990; 282(7): 442-5[PubMed]
  • 62. Nelson L, Messenger A, Karoo R, Thornton JW. 17beta-eatradiol but not 17alpha-estradiol inhibits human hair growth in whole follicle organ culture. J Invest Dermatol. 2003; 121(1): 821a
  • 63. Thornton MJ. The biological actions of estrogens on skin. Exp Dermatol. 2002; 11(6): 487-502[PubMed]
  • 64. Niiyama S, Happle R, Hoffmann R. Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol. 2001; 11(3): 195-8[PubMed]
  • 65. Riedel-Baima B, Riedel A. Female pattern hair loss may be triggered by low oestrogen to androgen ratio. Endocr Regul. 2008; 42(1): 13-6[PubMed]
  • 66. Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007; 5(5): 391-5[DOI][PubMed]
  • 67. Gassmueller J, Hoffmann R, Webster A. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol. 2008; 158(1): 109-15[DOI][PubMed]
  • 68. Georgala S, Katoulis AC, Georgala C, Moussatou V, Bozi E, Stavrianeas NG. Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology. 2004; 208(2): 178-9[DOI][PubMed]
  • 69. Mechanisms of low level light therapy. Biomedical Optics. 2006;
  • 70. Avram MR, Leonard RT, Jr, Epstein ES, Williams JL, Bauman AJ. The current role of laser/light sources in the treatment of male and female pattern hair loss. J Cosmet Laser Ther. 2007; 9(1): 27-8[DOI][PubMed]
  • 71. Karu T. Laser biostimulation: a photobiological phenomenon. J Photochem Photobiol B. 1989; 3(4): 638-40[PubMed]
  • 72. Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009; 29(5): 283-92[DOI][PubMed]
  • 73. Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012; 66(5): 794-800[DOI][PubMed]
  • 74. Caroli S, Pathomvanich D, Amonpattana K, Kumar A. Current status of hair restoration surgery. Int Surg. 2011; 96(4): 345-51[PubMed]
  • 75. Trueb RM. Association between smoking and hair loss: another opportunity for health education against smoking? Dermatology. 2003; 206(3): 189-91[PubMed]
  • 76. Trueb RM. Oxidative stress in ageing of hair. Int J Trichology. 2009; 1(1): 6-14[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments